by Megan Epperson, Ph.D., Analyst
| Apr 17, 2018
After anxiously awaiting readout from 3 pivotal trials of immunotherapy in NSCLC, we can finally take a breath to process what we learned at AACR 2018: KEYNOTE-189, IMpower 150, and CheckMate 227 all presented positive results yesterday. While the individual and cross-trial interpretations of these studies is complex, the near-term impact on the treatment of NSCLC appears rather simple.